These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 12477281)

  • 1. Development and effects of immunoliposomes carrying an antisense oligonucleotide against DHFR RNA and directed toward human breast cancer cells overexpressing HER2.
    Rodríguez M; Coma S; Noé V; Ciudad CJ
    Antisense Nucleic Acid Drug Dev; 2002 Oct; 12(5):311-25. PubMed ID: 12477281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of anti-sense oligonucleotides directed toward dihydrofolate reductase RNA in mammalian cultured cells.
    Rodríguez M; Noé V; Alemany C; Miralles A; Bemi V; Caragol I; Ciudad CJ
    Int J Cancer; 1999 May; 81(5):785-92. PubMed ID: 10328234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu.
    Roh H; Pippin J; Boswell C; Drebin JA
    J Surg Res; 1998 Jun; 77(1):85-90. PubMed ID: 9698539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.
    Kirpotin D; Park JW; Hong K; Zalipsky S; Li WL; Carter P; Benz CC; Papahadjopoulos D
    Biochemistry; 1997 Jan; 36(1):66-75. PubMed ID: 8993319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.
    Kirpotin DB; Drummond DC; Shao Y; Shalaby MR; Hong K; Nielsen UB; Marks JD; Benz CC; Park JW
    Cancer Res; 2006 Jul; 66(13):6732-40. PubMed ID: 16818648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
    Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
    Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced delivery of synthetic oligonucleotides to human leukaemic cells by liposomes and immunoliposomes.
    Ma DD; Wei AQ
    Leuk Res; 1996; 20(11-12):925-30. PubMed ID: 9009250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense-mediated exon skipping to shift alternative splicing to treat cancer.
    Wan J
    Methods Mol Biol; 2012; 867():201-8. PubMed ID: 22454063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of HIV replication by immunoliposomal antisense oligonucleotide.
    Selvam MP; Buck SM; Blay RA; Mayner RE; Mied PA; Epstein JS
    Antiviral Res; 1996 Dec; 33(1):11-20. PubMed ID: 8955849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective death of human breast cancer cells by lytic immunoliposomes: Correlation with their HER2 expression level.
    Barrajón-Catalán E; Menéndez-Gutiérrez MP; Falco A; Carrato A; Saceda M; Micol V
    Cancer Lett; 2010 Apr; 290(2):192-203. PubMed ID: 19896266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid screening method for antisense oligonucleotides against human growth factor receptor p185(erbB-2).
    Rohmann A; Lochmann D; Weyermann J; Bertling WM; Dingermann T; Zimmer A
    Oligonucleotides; 2004; 14(1):1-9. PubMed ID: 15104891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
    Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2/neu antisense targeting of human breast carcinoma.
    Roh H; Pippin JA; Green DW; Boswell CB; Hirose CT; Mokadam N; Drebin JA
    Oncogene; 2000 Dec; 19(53):6138-43. PubMed ID: 11156527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposomal delivery of antisense oligonucleotides for efficient downregulation of Bcl-2 and induction of apoptosis.
    Buck AC; Shen C; Schirrmeister H; Schmid-Kotsas A; Munzert G; Guhlmann A; Mehrke G; Klug N; Gross HJ; Bachem M; Reske SN
    Cancer Biother Radiopharm; 2002 Jun; 17(3):281-9. PubMed ID: 12136520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
    Xu FJ; Stack S; Boyer C; O'Briant K; Whitaker R; Mills GB; Yu YH; Bast RC
    Clin Cancer Res; 1997 Sep; 3(9):1629-34. PubMed ID: 9815853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of growth of human breast carcinoma cells by an antisense oligonucleotide targeted to the transferrin receptor gene.
    Yang DC; Jiang XP; Elliott RL; Head JF
    Anticancer Res; 2001; 21(3B):1777-87. PubMed ID: 11497259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intracellular routing in breast cancer cells of streptavidin-conjugated trastuzumab Fab fragments linked to biotinylated doxorubicin-functionalized metal chelating polymers.
    Liu P; Cai Z; Kang JW; Boyle AJ; Adams J; Lu Y; Ngo Ndjock Mbong G; Sidhu S; Reilly RM; Winnik MA
    Biomacromolecules; 2014 Mar; 15(3):715-25. PubMed ID: 24506198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced Antisense Oligonucleotide Delivery Using Cationic Liposomes Grafted with Trastuzumab: A Proof-of-Concept Study in Prostate Cancer.
    Sicard G; Paris C; Giacometti S; Rodallec A; Ciccolini J; Rocchi P; Fanciullino R
    Pharmaceutics; 2020 Nov; 12(12):. PubMed ID: 33260460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense oligodeoxynucleotide targeting HER2 mRNA sensitized docetaxel in breast cancer treatment.
    Sun J; Xu Y; Song S; Wu Z; Duan H
    Pharm Biol; 2011 Nov; 49(11):1167-72. PubMed ID: 22014264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temporary ex vivo inhibition of the expression of the human oncogene HER2 (NEU) by a triple helix-forming oligonucleotide.
    Porumb H; Gousset H; Letellier R; Salle V; Briane D; Vassy J; Amor-Gueret M; Israël L; Taillandier E
    Cancer Res; 1996 Feb; 56(3):515-22. PubMed ID: 8564964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.